ARTICLE | Emerging Company Profile
MiroBio: mapping the atlas of immune checkpoints
With an £80M series B, University of Oxford spinout is targeting immune suppressive signaling networks in autoimmune diseases
June 30, 2022 9:45 PM UTC
MiroBio is taking a systematic approach to identifying immune checkpoints with “inhibitory reserve” — room left to step on the brakes — for autoimmune disorders.
The University of Oxford spinout, which announced an £80 million ($98.6 million) series B round led by Medicxi on Wednesday, has raised a total of £107 million since its founding in 2018. ...
BCIQ Target Profiles